ALK and non-small cell lung carcinoma: Several of these small molecule ALK inhibitors have recently gone into phase 1 clinical trials for patients with refractory neuroblastoma, inflammatory myofibroblastic tumour, non-small-cell lung cancer (NSCLC) and anaplastic large-cell lymphoma (ALCL) [18, 19].